Biotest Stock Forecast for 2023 - 2025 - 2030
Updated on 04/25/2024
Biotest Stock Forecast and Price Target
The average price target for Biotest's stock set by recognized analysts recently is 37.00€, which would result in a potential upside of approximately 28.92% if it reached this mark. The estimation is based on a high estimate of 37.00€ and a low estimate of 37.00€. If you're looking to buy Biotest stock, you may also want to check out its rivals.
28.92% Upside
Biotest Fair Value Forecast for 2023 - 2025 - 2030
Biotest's Price has increased by 100.00% In the last four years, going from 0.00€ to 0.00€. In the next year, analysts expect Fair Value to reach 30.22€ – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
10
|
$571.73 | Buy/Sell | $591.94 | 7.57% |
| CSL Stock Forecast | CSL | Outperform |
12
|
$278.45 | Buy/Sell | $205.51 | -27.04% |
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$230.48 | Buy/Sell | $284.47 | 21.49% |
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.09k | Buy/Sell | ¥4.74k | 11.25% |
| GRF Stock Forecast | Grifols | Outperform |
18
|
8.09€ | Buy/Sell | 18.48€ | 134.86% |
Biotest Revenue Forecast for 2023 - 2025 - 2030
Biotest's Revenue has increased by 6.59% In the last two years, going from 484.20€M to 516.10€M. In the next year, analysts expect Revenue to reach 635.84€M – an increase of 23.20%. For the next seven years, the forecast is for Revenue to grow by 25.21%.
.jpg)
Biotest Dividend per Share Forecast for 2023 - 2025 - 2030
In the last year, Biotest's Dividend per Share has seen a drop from 0.04€ to 0.04€ – a 0.00% decrease. According to 1 major analysts, Biotest's Dividend per Share will fall by 50.00% in the next year, reaching 0.02€. Over the next seven years, experts anticipate that Biotest's Dividend per Share will grow at a rate of 1267.64%.
Biotest EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Biotest's EBITDA has fallen from 12.50€M to 10.40€M – a 16.80% decrease. Next year, analysts are expecting EBITDA to reach 54.91€M – an increase of 427.98%. Professionals believe that By 2030, Biotest's EBITDA will fall to -214.47€M – a 2162.22% decrease from its current value.
Biotest EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Biotest's EBIT has grown by 64.23%, rising from -12.30€M to -20.20€M. In the following year, 1 experts forecast that Biotest's EBIT will decrease by 178.71%, to 15.90€M. In 2030, professionals predict that Biotest's EBIT will decrease by 471.05%, to 74.95€M.
Biotest EPS Price Prediction Forecast for 2023 - 2025 - 2030
Biotest's EPS has increased by 100.00% In the last four years, going from -0.78€ to 0.00€. In the next year, analysts expect EPS to reach -0.10€ – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
.jpg)